Dabigatran for stroke prevention in nonvalvular atrial fibrillation: answers to challenging "real-world" questions

Jorge Ferreira, Daniel Ferreira, Miguel Viana-Baptista, Paulo Bettencourt, Rui Cernadas, Francisco Crespo

Research output: Contribution to journalReview articlepeer-review

5 Downloads (Pure)

Abstract

Dabigatran etexilate is a novel, oral, reversible, direct thrombin inhibitor that constitutes a major breakthrough for stroke prevention in patients with nonvalvular atrial fibrillation (AF). Dabigatran was the first new oral anticoagulant approved in Europe and became available in Portugal, for stroke prevention in nonvalvular AF, earlier than in most European countries. This paper is the joint effort of a panel of experts from different specialties and provides information on the use of dabigatran, in anticipation of the challenges that will come with increased usage.

Original languageEnglish
Article number867121
Pages (from-to)Online
Number of pages10
JournalThrombosis
Volume2012
DOIs
Publication statusPublished - 2012

Keywords

  • Journal Article

Fingerprint

Dive into the research topics of 'Dabigatran for stroke prevention in nonvalvular atrial fibrillation: answers to challenging "real-world" questions'. Together they form a unique fingerprint.

Cite this